Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications

Blood

Volumn 103, Issue 3, 2004, Pages 1011-1019

  Leen, Ann M ^b   Sili, Uluhan ^b   Savoldo, Barbara ^b   Jewell, Alan M ^b   Piedra, Pedro A ^b   Brenner, Malcolm K ^b   Rooney, Cliona M ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; CD8 ANTIGEN;

ADENOVIRUS; ARTICLE; CLINICAL ARTICLE; CROSS REACTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOTHERAPY; MEMORY CELL; MONONUCLEAR CELL; MORBIDITY; MORTALITY; NORMAL HUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SEROTYPE; TARGET CELL; VIRUS INFECTION;

EID: 1342323794     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2449     Document Type: Article

References (42)

1. Horwitz MS. Adenoviruses. In: Fields Virology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:2301-2326.
2. Shenk TE. Adenoviridae: the viruses and their replication. In: Fields Virology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001: 2265-2300.
3. Horvath J, Palkonyay L, Weber J. Group C adenovirus DNA sequences in human lymphoid cells. J Virol. 1986;59:189-192.
4. Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood. 2002;100:1619-1627.
5. Hale GA, Heslop HE, Krance RA, et al. Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant. 1999;23:277-282.
6. Lion T, Baumgartinger R, Watzinger F, et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood. 2003;102:1114-1120.
7. Heslop HE, Li C, Krance RA, Loftin SK, Rooney CM. Epstein-Barr infection after bone marrow transplantation. Blood. 1994;83:1706-1708.
8. Zaia JA, Sissons JG, Riddell S, et al. Status of cytomegalovirus prevention and treatment in 2000. Hematology (Am Soc Hematol Educ Program). 2000;339-355.
9. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063-4071.
10. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000;95:1502-1505.
11. Rooney CM, Smith CA, Ng C, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet. 1995;345:9-13.
12. Riddell SR, Walter BA, Gilbert MJ, Greenberg PD. Selective reconstitution of CD8 + cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cells clones. Bone Marrow Transplant. 1994;14:S78-S84.
13. Chakrabarti S, Collingham KE, Fegan CD, Milligan DW. Fulminant adenovirus hepatitis following unrelated bone marrow transplantation: failure of intravenous ribavirin therapy. Bone Marrow Transplant. 1999;23:1209-1211.
14. Ribaud P, Scieux C, Freymuth F, Morinet F, Gluckman E. Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Clin Infect Dis. 1999;28:690-691.
15. Miyamura K, Hamaguchi M, Taji H, et al. Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors. Bone Marrow Transplant. 2000;25:545-548.
16. Legrand F, Berrebi D, Houhou N, et al. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant. 2001;27:621-626.
17. Hromas R, Clark C, Blanke C, et al. Failure of ribavirin to clear adenovirus infections in T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994;14:663-664.
18. Bordigoni P, Carret AS, Venard V, Witz F, Le Faou A. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2001;32:1290-1297.
19. Rawle FC, Knowles BB, Ricciardi RP, et al. Specificity of the mouse cytotoxic T lymphocyte response to adenovirus 5. E1A is immunodominant in H-2b, but not in H-2d or H-2k mice. J Immunol. 1991;146:3977-3984.
20. Sparer TE, Wynn SG, Clark DJ, et al. Generation of cytotoxic T lymphocytes against immunorecessive epitopes after multiple immunizations with adenovirus vectors is dependent on haplotype. J Virol. 1997;71:2277-2284.
21. Flomenberg P, Piaskowski V, Truitt RL, Casper JT. Characterization of human proliferative T cell responses to adenovirus. J Infect Dis. 1995;171:1090-1096.
22. Olive M, Eisenlohr LC, Flomenberg P. Quantitative analysis of adenovirus-specific CD4+ T-cell responses from healthy adults. Viral Immunol. 2001;14:403-413.
23. Olive M, Eisenlohr L, Flomenberg N, Hsu S, Flomenberg P. The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope. Hum Gene Ther. 2002;13:1167-1178.
24. Hamel Y, Blake N, Gabrielsson S, et al. Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapy. Hum Gene Ther. 2002;13:855-866.
25. Einfeld DA, Roelvink PW. Advances towards targetable adenovirus vectors for gene therapy. Curr Opin Mol Ther. 2002;4:444-451.
26. Palmer DH, Mautner V, Kerr DJ. Clinical experience with adenovirus in cancer therapy. Curr Opin Mol Ther. 2002;4:423-434.
27. Rooney CM, Aguilar LK, Huls MH, Brenner MK, Heslop HE. Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol. 2001;258:221-229.
28. Zajac AJ, Murali-Krishna K, Blattman JN, Ahmed R. Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. Curr Opin Immunol. 1998;10:444-449.
29. Smith CA, Woodruff LS, Kitchingman GR, Rooney CM. Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro. J Virol. 1996;70:6733-6740.
30. Smith CA, Woodruff LS, Rooney C, Kitchingman GR. Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. Hum Gene Ther. 1998;9:1419-1427.
31. Smith CA, Ng CYC, Loftin SK, et al. Adoptive immunotherapy for Epstein-Barr virus-related lymphoma. Leuk Lymphoma. 1996;23:213-220.
32. Shayakhmetov DM, Lieber A. Dependence of adenovirus infectivity on length of the fiber shaft domain. J Virol. 2000;74:10274-10286.
33. Yotnda P, Onishi H, Heslop HE, et al. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 2001;8:930-937.
34. Sili U, Huls MH, Davis AR, et al. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocytes using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother. 2003;26:241-256.
35. Leen A, Meij P, Redchenko I, et al. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol. 2001;75:8649-8659.
36. Meij P, Leen A, Rickinson AB, et al. Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int J Cancer. 2002;99:93-99.
37. Yang J, Lemas VM, Flinn IW, Krone C, Ambinder RF. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. Blood. 2000;95:241-248.
38. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. 4th ed. Philadelphia, PA: Lippincott, Williams & Williams; 2001:2575-2628.
39. Wold WSM, Gooding LR. Region E3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions. Virology. 1991;184:1-8.
40. Boon AC, de Mutsert G, Graus YM, et al. The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and -B phenotype. J Virol. 2002;76:582-590.
41. Regn S, Raffegerst S, Chen X, Schendel D, Kolb HJ, Roskrow M. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant. Bone Marrow Transplant. 2001;27:53-64.
42. Flomenberg P, Babbitt J, Drobyski WR, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis. 1994;169:775-781.